Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Real-World Experience With Pacritinib in the US
Real-World Experience With Pacritinib in the US
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Improving Transfusion Independence With JAK Inhibitor Therapy
Improving Transfusion Independence With JAK Inhibitor Therapy
Managing Myelofibrosis-Associated Thrombocytopenia
Managing Myelofibrosis-Associated Thrombocytopenia
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
Evaluation of the complex cardiac pathophysiology in HCM
Evaluation of the complex cardiac pathophysiology in HCM
Recommendations on the management of HCM in guidelines: European vs. American views
Recommendations on the management of HCM in guidelines: European vs. American views
